Physician profile
Robert S Burnstein
NPI 1295827350
$17,715.59
in general payments reported to CMS, 2019-2025
36 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,571 · 2020: $1,482 · 2021: $2,258 · 2022: $7,287 · 2023: $1,769 · 2024: $1,224 · 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,117.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $6,380.15 | 2021-2025 | Qelbree, Qelbree |
| Validus Pharmaceuticals LLC | $1,543.03 | 2019-2025 | Raldesy, Equetro, Equetro |
| Otsuka America Pharmaceutical, INC. | $1,180.55 | 2019-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Lundbeck LLC | $1,152.38 | 2019-2025 | Rexulti |
| Abbvie INC. | $659.94 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $612.78 | 2019-2022 | |
| Alkermes, INC. | $607.70 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $574.12 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $463.29 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $456.07 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $412.37 | 2019-2025 | Trintellix |
| Corium, LLC | $397.68 | 2022-2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $370.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $368.14 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.98 | 2020-2025 | Caplyta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $348.27 | 2019-2020 | |
| Axsome Therapeutics, INC. | $304.85 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $301.74 | 2021-2025 | |
| Bausch Health US, LLC | $192.49 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $126.81 | 2019-2024 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $105.69 | 2020-2022 | |
| Adlon Therapeutics L.P. | $102.91 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $102.05 | 2022-2024 | Quviviq |
| Eisai INC. | $100.87 | 2020 | |
| Harmony Biosciences LLC | $90.28 | 2020-2021 | |
| Tris Pharma INC | $83.97 | 2023-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $64.21 | 2021-2022 | |
| Shire North American Group INC | $50.82 | 2019 | |
| Collegium Pharmaceutical, INC. | $40.98 | 2025 | Jornay Pm |
| Neuronetics, INC. | $37.10 | 2020-2023 | Neurostar Tms Therapy System |
| Neos Therapeutics, Lp | $33.31 | 2019 | |
| Owp Pharmaceuticals, INC. | $30.61 | 2020-2023 | Subvenite, Lamotrigine |
| Noven Therapeutics, LLC | $21.38 | 2025 | Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.43 | 2023 | Rexulti |
| Lilly USA, LLC | $13.82 | 2025 | Kisunla |
| Arbor Pharmaceuticals, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Burnstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.